Sales miss while gross margin and costs impressed in Q2. Growth set to recover, adj. EBITA intact and EPS +2-3%. Case remains, we stick to BUY, TP SEK 17 (15).
We expect -10% organic growth in Q2e, before the tide turns. Refreshment cycle, Windows 11 and AI to drive 2024 PC recovery. Minor estimate revisions, we stick to BUY, TP SEK 15.
Balance sheet fixed, growth to recover and margins on the rise. 12% adj. EBITA CAGR for '22/'23-'25/'26e. Valuation now attractive, up to BUY (Hold), TP of SEK 15 (10).
SEK 1.75bn rights issue done and in the numbers, 4x more shares. Market remains muted with weak IT capex and PC/smartphone sales. Adj. EBITA -1%, EPS -73%; HOLD, TP SEK 10 (18).
Disappointing growth and slow recovery, adj. EBITA -8-12%. Rights issue coming up, terms yet unknown, not included in estimates. We remain cautious on growth recovery: HOLD. TP SEK 18 (24).
We reduce adj. EBITA 4-8% on lower demand & tougher competition. 4.5x leverage in Q3 could go up in Q4e, increasing equity issue risk. To risky for us, we stick to HOLD, TP SEK 24 (32).
We estimate -3% org growth and -21% adj. EBITA y-o-y in Q3e. Adj. EBITA cut -5-8%, leverage to take a step up from 4.4x in Q2. Low valuation but rights issue risk remains: HOLD.
Leverage better than feared and inventory guidance compelling. But earnings momentum still under pressure, adj. EBITA -1-3%. Less risk of an equity issue, we raise TP but stick to HOLD.
Demand indicators continue to be under pressure. Adj. EBITA 2022/23e -10% on lower SMB assumptions. Balance sheet shape key for the share, we stick to HOLD.